Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease
Camille Cohen(Inserm), Frank Bridoux(Université de Poitiers), Bertrand Knebelmann(Hôpital Necker-Enfants Malades), Arnaud Jaccard(Centre Hospitalier Universitaire de Limoges), Guy Touchard(Centre Hospitalier Universitaire de Poitiers), Vincent Javaugue(Université de Poitiers), Jean‐Paul Fermand(Sorbonne Université), Raphaël Szalat(Boston University), Bruno Royer(Centre Hospitalier Universitaire Amiens-Picardie), Khalil El Karoui(Inserm), Alexis Caulier(Broad Institute), Sylvie Chevret(Saint Louis University Hospital), Bertrand Arnulf(Université Paris Cité)
Cited by 139
Related Papers
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
|Kidney International|2021|2.5k
Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study
|The Lancet|2012|1k
New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes
|Journal of Clinical Oncology|2012|965
Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases
|Kidney International|2021|809